Safety, tolerability, and immunogenicity of a 31-valent pneumococcal conjugate vaccine (VAX-31) in healthy adults aged 50 years and older from the USA: a phase 1/2, double-blinded, active-controlled, parallel-group, dose-finding randomised clinical trial
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The Lancet. Infectious diseases
- Publicado em
- 18 mar 2026
- Citações
- 2
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Safety, tolerability, and immunogenicity of a 31-valent pneumococcal conjugate vaccine (VAX-31) in healthy adults aged 50 years and older from the USA: a phase 1/2, double-blinded, active-controlled, parallel-group, dose-finding randomised clinical trial
James Wassil, Jeff Fairman, Carlos A Fierro, James Clark, Sean Bennett, Derek Johnson, Qin Jiang, Thi-Sau Migone, Alexandra Paschenko, Jakub K Simon et al.
Descritores MeSH
- Streptococcus pneumoniae
- Pneumococcal Infections
- Pneumococcal Vaccines
- Immunogenicity, Vaccine
- Female
- Humans
- Immunoglobulin G
- Male
- Middle Aged
- United States